This Day On The Street
Continue to site right-arrow
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
TheStreet Open House

AmSurg Reports Fourth-Quarter Net Earnings Per Diluted Share From Continuing Operations Of $0.44 Including NSC Transaction Costs Of $0.02

Stocks in this article: AMSG

Christopher A. Holden, President and Chief Executive Officer of AmSurg Corp. (NASDAQ: AMSG), today announced financial results for the fourth quarter and year ended December 31, 2011. Revenues for the fourth quarter were $223,336,000, an increase of 22% from $183,371,000 for the fourth quarter of 2010. Net earnings from continuing operations attributable to AmSurg common shareholders were $13,697,000, or $0.44 per diluted share, for the fourth quarter of 2011 compared with $13,183,000, or $0.43 per diluted share, for the fourth quarter of 2010. Adjusted net earnings from continuing operations per diluted share attributable to AmSurg common shareholders were $0.46 for the fourth quarter of 2011, which excluded transaction costs of $0.02 related to the National Surgical Care (“NSC”) transaction. The results for the fourth quarter of 2011 included an incremental negative impact of $0.01 per diluted share from the revision of the Medicare payment system for ASCs. The operations of the acquired NSC centers contributed $0.04 per diluted share to net earnings from continuing operations attributable to AmSurg common shareholders for the quarter.

Revenues for 2011 increased 12% to $786,870,000 from $703,439,000 for 2010. Net earnings from continuing operations attributable to AmSurg common shareholders were $51,199,000, or $1.64 per diluted share, for 2011 compared with $51,144,000, or $1.67 per diluted share, for 2010. Adjusted net earnings from continuing operations per diluted share attributable to AmSurg common shareholders were $1.71 for 2011, which excluded NSC transaction costs of $0.07. The results for 2011 included an incremental negative impact of $0.05 per diluted share from the revision of the Medicare payment system for ASCs and $0.07 per diluted share from the higher interest costs related to the refinancing of the Company’s credit facility in May 2010 and a higher effective tax rate. The operations of the acquired NSC centers contributed $0.05 per diluted share to net earnings from continuing operations attributable to AmSurg common shareholders for 2011.

1 of 6

Check Out Our Best Services for Investors

Action Alerts PLUS

Jim Cramer and Stephanie Link reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

Jim Cramer's protégé, David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
Try it NOW
Try it NOW
Try it NOW

Check Out Our Best Services for Investors

Dividend Stock Advisor

Jim Cramer's protégé, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Options Profits

Our options trading pros provide over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • Actionable options commentary and news
  • Real-time trading community
Try it NOW
Try it NOW
Try it NOW
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!

Markets

DOW 17,389.97 -288.73 -1.63%
S&P 500 2,033.74 -23.35 -1.14%
NASDAQ 4,694.6530 -77.11 -1.62%

Partners Compare Online Brokers

Free Reports

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs